BioLineRx Ltd.

_________ false


	Israel Securities Authority			Tel Aviv Stock Exchange		C001 ( Public )		Reported via MAGNA:	28/03/2024
	www.isa.gov.il			www.tase.co.il				Reference:	2024-02-027916	Time of broadcast: 10:04 10:04

Amended report for distorted report sent on date 26/03/2024 Whose reference number was: 2024-02-032028


The distortion:	Typo
The distortion cause:	Human error
The main amendment:	See the Explanatory Note at the Form 20-F/A

Report of Periodic or Interim ReportRegulation 3 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000


	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onForm 20-F/A (Amendment No. 1)

Form_20-F_A_Amend_No1_isa.pdf

Link to filing on foreign stock exchange (optional): _________



References of previous documents relating to this matter(the reference does not constitute incorporation by reference):


- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 20/02/2024
Address: HaMa'ayan 2 , Modi'in 7177871 , Israel Tel: 08-6429100 , Fax: 08-6429101
E-mail address: [email protected] Company site: www.biolinerx.com

Previous names of reporting entity:

Name of the Signatory: Serlin Philip Adam Position of Signatory in the reporting corporation: Chief Executive Officer Name of Employer Company:
Address: HaMa'ayan 2 , Modi'in 7177871 Telephone: 08-6429100 Facsimile: 08-6429101 E-mail: [email protected] 1
Israel

AI Terminal